GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Notable Labs Ltd (NAS:NTBL) » Definitions » Debt-to-Equity

Notable Labs (Notable Labs) Debt-to-Equity : 0.14 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Notable Labs Debt-to-Equity?

Notable Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.52 Mil. Notable Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.53 Mil. Notable Labs's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $15.11 Mil. Notable Labs's debt to equity for the quarter that ended in Dec. 2023 was 0.14.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Notable Labs's Debt-to-Equity or its related term are showing as below:

NTBL' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.03   Med: -0.01   Max: 0.14
Current: 0.14

During the past 3 years, the highest Debt-to-Equity Ratio of Notable Labs was 0.14. The lowest was -0.03. And the median was -0.01.

NTBL's Debt-to-Equity is ranked better than
51.08% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs NTBL: 0.14

Notable Labs Debt-to-Equity Historical Data

The historical data trend for Notable Labs's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Notable Labs Debt-to-Equity Chart

Notable Labs Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-Equity
-0.03 -0.01 0.14

Notable Labs Semi-Annual Data
Dec21 Dec22 Dec23
Debt-to-Equity -0.03 -0.01 0.14

Competitive Comparison of Notable Labs's Debt-to-Equity

For the Biotechnology subindustry, Notable Labs's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Notable Labs's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Notable Labs's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Notable Labs's Debt-to-Equity falls into.



Notable Labs Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Notable Labs's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Notable Labs's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Notable Labs  (NAS:NTBL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Notable Labs Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Notable Labs's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Notable Labs (Notable Labs) Business Description

Traded in Other Exchanges
N/A
Address
320 Hatch Drive, Foster City, CA, USA, 94404
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic.